Background-Periodic limb movements during sleep (PLMS) cause repetitive sympathetic activation and may be associated with increased cardiovascular risk. We hypothesized that PLMS frequency (periodic limb movement index [PLMI]) and PLMS arousal frequency (periodic limb movement arousal index [PLMAI]) are predictive of incident cardiovascular disease, including coronary heart disease, peripheral arterial disease, and cerebrovascular disease, in an elderly male cohort.
P eriodic limb movements during sleep (PLMS) are spontaneously occurring movements of the legs that occur repetitively throughout the sleeping period. They occur in Ϸ5% to 8% of the general population and increase in prevalence with age. [1] [2] [3] Individual limb movements last up to 5 seconds and consist of foot dorsiflexion and less often flexion at the knee or hip. 4 Movements occur approximately every 30 seconds and in severe cases can number well into the hundreds each night. 5 The clinical significance of these movements is unclear; however, when PLMS are associated with arousal, the result can be sleep fragmentation with potential sympathetic nervous system overactivity. 6 -9 Periodic limb movements occur in a wide variety of disease states, most notably essential hypertension, stroke, congestive heart failure, and the restless legs syndrome (RLS). 10 -13 The presence of PLMS in both end-stage renal disease and systolic heart failure has been shown to increase mortality risk. 14, 15 
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Singular limb movements comprising PLMS are each accompanied by a discrete elevation in blood pressure by Ϸ10 to 20 mm Hg and in heart rate by about 10 bpm. 8, 9 Studies of PLMS have also suggested that hypertension may persist in the daytime, but this association has not been demonstrated uniformly. 10, 16, 17 Children with PLMS also demonstrate a nondipping nocturnal blood pressure pattern that normalizes during the day. 18 Theoretically, these repetitive sympathetic accelerations could result in increased cardiovascular risk. However, prior research has not yet established a link between PLMS and increased incidence of cardiovascular events.
Increased cardiovascular risk has been associated with RLS in population studies. 19, 20 A sensorimotor disorder, RLS is characterized by an inexorable urge to move at night, a time when the body is at greatest need for rest. Periodic limb movements may represent an endophenotype for RLS because they occur in the great majority of RLS cases and share a common genetic variant with RLS. 13, 21, 22 Early observations suggested that persons with RLS were more likely than those without RLS to have a history of hypertension. 17 In studies using more rigorous statistical adjustment, RLS was found to be associated with prevalent cardiovascular disease, including stroke and myocardial infarction, but not hypertension. 19, 20 These studies, however, considered only prevalent cardiovascular disease, leaving unclear directionality and ultimately causality. An additional limitation results from the inherent subjectivity of RLS, making quantification of disease severity difficult. Measurement of PLMS provides an objective means for defining a phenotype showing specific genetic linkages to RLS. 21 Therefore, we hypothesized that both PLMS and PLMS arousal frequency are predictive of incident cardiovascular disease, including coronary heart disease, peripheral vascular disease, and stroke/transient ischemic attack, in an elderly male cohort. Data from the Outcomes of Sleep Disorders in Older Men Study (MrOS Sleep Study), a large cohort designed to examine sleep-related outcomes, were analyzed to test these hypotheses. Two hundred forty-four men in the Sleep Study cohort were missing polysomnography data because either the measure was not performed (nϭ179) or the collected data were unusable owing to poor signal quality (nϭ45). Men missing poly-somnography data were more likely to be of minority race, more likely to have depression, and less likely to have prevalent cardiovascular disease (PϽ0.05). Protocols were approved by the Institutional Review Board at each site, and participants provided signed informed consent.
Methods

Participants
Polysomnography
Sleep testing was conducted with unattended in-home polysomnography (Safiro, Compumedics, Inc, Melbourne, Australia). The recording montage included the following: C3/A2 and C4/A1 electroencephalography, bilateral electrooculography, submental electromyography, thoracic/abdominal respiratory inductance plethysmography, naso-oral thermistry, nasal pressure transduction, oximetry, ECG, and bilateral anterior tibialis piezoelectric movement sensors. Centrally trained staff performed home visits for unit setup and impedance value verification for each channel as previously described. 25 Data were downloaded to a central server at the Central Sleep Reading Center (Cleveland, OH) and scored by certified research polysomnologists using standard criteria. 26, 27 Apnea was defined as Ͼ90% decrement in thermistry amplitude for at least 10 seconds; hypopnea was defined as at least 30% reduction in nasal pressure transduction or summed inductance bands for at least 10 seconds. This analysis included only apneas and hypopneas associated with Ն4% desaturation. The apnea-hypopnea index was calculated as the total number of apneas and hypopneas per hour of sleep. Arousals were scored according to the American Academy of Sleep Medicine criteria. 27 The arousal index was calculated as the number of arousals per hour of sleep.
We scored PLMS according to standard American Academy of Sleep Medicine criteria in which individual movements were scored as a PLMS if the duration was between 0.5 and 5 seconds and when there was a clear amplitude increase from baseline in leg channels. 28 To be considered periodic, at least 4 movements needed to occur in succession no less than 5 seconds and no more than 90 seconds apart. The periodic limb movement index (PLMI) was the total number of periodic leg movements per hour of sleep. Leg movements after respiratory events were excluded unless they were part of a Ն4movement cluster with at least 2 movements occurring independently of respiratory events. The periodic limb movement arousal index (PLMAI) was the total number of periodic leg movements per hour of sleep in which EEG arousal occurred within 3 seconds of movement termination. 29 We examined PLMI and PLMAI in categories (roughly tertiles): PLMI Ͻ5, 5 to Ͻ30, and Ն30; and PLMAI Ͻ1, 1 to Ͻ5, and Ն5.
Incident Cardiovascular Disease Events
Participants were surveyed for potential incident cardiovascular events by postcard and/or phone contact every 4 months with a Ͼ99% response rate. Relevant medical records and supporting documentation from any potential incident event, including death certificates for fatal events, were obtained by the clinical center and forwarded to the coordinating center for centralized adjudication. When no medical records were available for out-of-hospital deaths, proxy interviews with the next of kin were obtained. For both nonfatal and fatal cardiovascular events, all documents were adjudicated by a board-certified cardiologist using a prespecified adjudication protocol developed with methods that had been used successfully at the coordinating center for both prior randomized trials and epidemiological studies of cardiovascular disease. Interrater agreement was periodically evaluated by Ն1 expert adjudicators in a random subset of events to ensure quality control in the outcomes adjudication process.
Confirmed cardiovascular events were grouped as follows: (1) coronary heart disease (CHD) event: acute myocardial infarction (ST-segment or non-ST-segment elevation), sudden coronary heart disease death, coronary artery bypass surgery, mechanical coronary revascularization, hospitalization for unstable angina, ischemic congestive heart failure, or other CHD event not described above; (2) cerebrovascular disease (CBD) event: stroke or transient ischemic attack; (3) peripheral arterial disease (PAD) event: acute arterial occlusion, rupture, dissection, or vascular surgery for arterial dis-ease; and (4) all-cause cardiovascular disease (cCVD) event: CHD, CBD, and PAD combined.
Other Measurements
Participants completed questionnaires on demographics, medical history, physical activity, smoking, and alcohol use. History of coronary heart disease was defined as prior diagnosis of myocardial infarction, angina, bypass surgery, or angioplasty by self-report. History of peripheral vascular disease was defined as prior diagnosis of intermittent claudication, aortic aneurysm repair, angioplasty, or bypass procedure of lower-extremity arteries or carotid endarterectomy. Prescription and nonprescription medications were inventoried, verified by pill bottle examination, and matched to ingredient(s) with the Iowa Drug Information Service Drug Vocabulary (College of Pharmacy, University of Iowa, Iowa City). 30 The Geriatric
Depression Scale was used with depression defined using the standard Ն6 cutoff. 31 The Physical Activity Scale for the Elderly measured the level of physical activity. 32 Resting blood pressure, weight, height, and body mass index (BMI) were also measured. Prevalent hypertension was defined by one or more of the following criteria: hypertension self-report, antihypertensive medications use, or systolic or diastolic blood pressure Ն140 or 90 mm Hg, respectively. Incident hypertension was defined similarly at follow-up Ϸ3.4Ϯ0.5 years later. Cases of incident hypertension were not confirmed by an adjudicator. Of the 923 men without prevalent hypertension at baseline, 102 were missing data on incident hypertension. Of these 102, 7 had terminated before the follow-up visit, 2 refused to participate in the visit, and 61 had died before the follow-up visit. Thirty-two attended the follow-up visit but were missing information needed to calculate incident hypertension status. PLMI indicates periodic limb movement index; BMI, body mass index; AHI, apnea-hypopnea index; PASE, Physical Activity Scale for the Elderly; TIA, transient ischemic attack; CBD, cerebrovascular disease; CHD, coronary heart disease; PAD, peripheral arterial disease; and BP, blood pressure. Data are shown as meanϮSD when appropriate. CBD includes stroke and TIA. CHD includes myocardial infarction, angina, coronary bypass surgery, and angioplasty. PAD includes intermittent claudication, repair of aortic aneurysm, bypass procedure on arteries in the legs, angioplasty of lower-extremity arteries, and carotid endarterectomy. P values for continuous variables are from ANOVA for normally distributed variables (age, BMI, PASE score, systolic and diastolic blood pressure) and Kruskal-Wallis test for skewed data (AHI, arousal index). P values for categorical data are from 2 test for homogeneity (race, smoking status, alcohol intake, benzodiazepine use, antidepressant use, dopaminergic use, depression, diabetes mellitus, CBD, CHD, myocardial infarction, PAD, hypertension, antihypertensive use, hypertension history).
Statistical Analysis
Participant characteristics were compared for PLMI and PLMAI by use of the 2 test for categorical variables, ANOVA for normally distributed continuous variables, and Kruskal-Wallis tests for continuous variables with skewed distributions.
Cox proportional hazards regression was used to assess the association between PLMI and PLMAI and risk of additional cardiovascular disease event; results are presented as hazard ratios with 95% confidence intervals. Models were unadjusted and then minimally adjusted for age, clinic, and BMI. Additional covariates were included in a multivariate model and were selected if they were related to PLMI or PLMAI at PϽ0.10 or were known risk factors for cCVD. Final model predictors included age, clinic site, BMI, race, depression, prevalent hypertension, diabetes mellitus, smoking, alcohol intake, physical activity, apnea-hypopnea index, antidepressant use, and benzodiazepine use. For a predictor with 3 groups roughly in tertiles, there is 80% power to detect an adjusted relative hazard for these outcomes ranging from 1.20 to 1.54 when comparing the lowest and highest tertiles (CHD relative hazardϭ1.27, CBD relative hazardϭ1.47, PAD relative hazardϭ1.54 and cCVD relative hazardϭ1.20).
It is possible that PLMI or PLMAI is related to unmeasured confounders that make mortality more likely. In the case of these competing measured or unmeasured risk factors, men with the highest PLMI or PLMAI would develop fewer cCVD events because of higher mortality. To address this possibility, the Fine and Gray 33 model was integrated into multivariate models to calculate the hazard ratio (95% confidence interval), allowing for the competing risk of mortality.
Secondary analyses were performed by adding previous diagnosis of each outcome as a covariate in the multivariate model. Interaction of PLMI and PLMAI with prevalent hypertension was explored by constructing models adjusted for clinic site, age, BMI, PLMI or PLMAI, prevalent hypertension, and the interaction of prevalent hypertension and PLMI/PLMAI. Clinic site was adjusted for to account for potential differences by site in measures related to covariates. Stratifications by this parameter were performed when the P for interaction was Ͻ0.10. Interaction models were limited to cCVD outcome owing to small event counts for other outcomes. Sensitivity analyses were performed by removing men who were taking dopaminergic medications (nϭ33) and then separately by removing men who had an apnea-hypopnea index Ն5 (nϭ880); results were largely similar.
The association of PLMI and PLMAI with incident hypertension was examined by the use of logistic regression, with results presented as odds ratios and 95% confidence intervals. Men with prevalent hypertension (nϭ1986) were not included in these analyses. Similar minimally and multivariate adjusted models were performed as described above. All significance levels reported were 2 sided. Analyses were conducted with SAS version 9.2 (SAS Institute Inc, Cary, NC).
Results
Of the 3135 MrOS Sleep Study cohort participants, 2911 underwent polysomnography with PLMS measurement and were included in this analysis. These participants were followed up for 4.4Ϯ0.8 years (range, 9 days to 5.4 years) for incident events. During this time period, 345 men (11.9%) had a CHD event, 117 (4.1%) had a CBD, 98 (3.4%) had a PAD event, and 500 (17.3%) had at least 1 cCVD event. Table 1 shows demographic characteristics, cardiovascular risk factors, and diseases for the overall cohort and cohort by PLMI category. In total, 2063 men or 70.9% of the cohort had a PLMI Ͼ5. High-PLMI categories were associated with increasing age and arousal index, white race, depression, and prevalent hypertension, CHD, and myocardial infarction. We found that 1751 men or 60.2% of the cohort had a PLMAI Ͼ1. High-PLMAI categories were associated with increasing age, apnea-hypopnea index, arousal index, white race, and prevalent CHD and myocardial infarction (data not shown). Neither index was associated with smoking status, alcohol intake, or prevalent CBD.
Data on incident hypertension were available for 821 of 923 men without prevalent hypertension at the follow-up visit Ϸ3.4 years later. In this sample, 258 (31.4%) developed hypertension. Although higher levels of PLMI were associated with an unadjusted increase in the rate of prevalent hypertension (Table 1) , there was no association between PLMI and incident hypertension with adjustment, nor was there an association between prevalent or incident hypertension and PLMAI ( Table 2) .
In fully adjusted models, compared with the referent PLMAI Ͻ1 group, the highest category of PLMAI was associated with a 26% increased hazard rate for incident cCVD (Table 3) , with risk increasing linearly across the categories (P for trendϭ0.04), as shown in the survival curve ( Figure 1) . A similar association was seen for PLMI category and cCVD, with men in the 5ՅPLMIϽ30 and PLMI Ն30 groups having a 25% to 31% increased risk compared with the reference group. In models adjusted for age, BMI, and clinic site, PLMI Ն30 was associated with a 31% increased hazard rate for incident CHD compared with the PLMI Ͻ5 category, but this was no longer significant after further adjustment. Additionally, the 2 higher-PLMI categories compared with the referent group had an Ϸ2-fold increased hazard rate for incident PAD. This is shown in the survival curve in Figure 2 , which shows that both high-PLMI categories confer similar increased risk of incident PAD. Incident CBD was not associated with PLM category. Results were not materially affected by further adjustment for previous There was evidence for an interaction between PLMS frequency and prevalent hypertension relative to incident cCVD ( Table 4 ). The P values for the interaction terms for PLMS and prevalent hypertension met our prespecified criteria for significance (PϽ0.10), implying that the effect of PLMS on CVD depends on prevalent hypertension status. When further stratified by prevalent hypertension, high-PLMS categories were significantly associated with incident cCVD in fully adjusted models only for those without prevalent hypertension, in whom the risk of incident cCVD was 66% to 89% higher for the elevated-PLM categories compared with the referent group. There was no significant association between either PLMI or PLMAI and incident cCVD in participants with prevalent hypertension.
Discussion
In this community-based elderly male population, PLMS frequency, with and without arousal, was associated with increased incidence of cCVD. Compared with men in the lowest-PLMI and -PLMAI groups, men with PLMI Ն30 and PLMAI Ն5 experienced a respective 25% and 26% increased cCVD incidence. Furthermore, this association was modified by hypertension, so that among men who were nonhypertensive at baseline, elevated PLMS were associated with an Ϸ2-fold increased cCVD incidence. In addition, PLMI Ն30 was associated with a 2-fold increased PAD incidence rate. These relationships persisted after consideration of multiple covariates, including (but not limited to) age, BMI, apneahypopnea index, blood pressure, diabetes mellitus, and hypertension. Significant associations were not demonstrated between PLMS and incident CBD or CHD; however, low event rates could have influenced these results by reducing precision and statistical power. This report extends prior cross-sectional reports and provides evidence that PLMS are associated with both incident cCVD and PAD in elderly men. These longitudinal data from a nonclinic sample support a causal role for increased PLMS and incident vascular disease.
Several mechanisms may explain the relationship between PLMS and cCVD. Prior research has shown that PLMS in persons with RLS are accompanied by discrete increases in blood pressure and heart rate. 8, 9 Chronic elevations of blood pressure in association with PLMS also have been reported in PLMI indicates periodic limb movement index; PLMAI, periodic limb movement arousal index. Note that 2 participants lack the data necessary to determine prevalent hypertension status. Values in parentheses are 95% confidence intervals.
*P values for interaction with prevalent hypertension for PLMIՆ30 category and when examining PLMAI as a continuous variable.
†Adjusted for clinic site, age, BMI, race, depression, prevalent diabetes mellitus, smoking, alcohol use, physical activity, use of antidepressants, use of benzodiazepines, and apnea-hypopnea index. some 10, 16 but not all prior studies. 17 The relationship between RLS and hypertension is similarly unclear. 17, 19, 20 In our study, men with PLMI Ն30 were more likely than men with PLMI Ͻ5 to have prevalent hypertension, but elevated PLMI was not associated with incident hypertension. The inability to detect association between incident hypertension and PLMS may have resulted from limited power, given the high frequency of prevalent hypertension in this elderly cohort or the presence of competing risk factors for hypertension such as smoking or obesity. Additionally, PLMS and hypertension may have a stronger relationship in younger populations, as is the case in obstructive sleep apnea. 34 In addition to discrete elevations in blood pressure with movements, PLMS have been associated with nocturnal hypertension in children. 18 Nondipping blood pressure has been associated with increased cardiovascular morbidity. 35, 36 Future studies in adult populations are needed to assess whether increased cCVD risk associated with PLMS works through a mechanism of nocturnal hypertension. In this analysis, incident cCVD was more strongly associated with increased PLMS in men without baseline hypertension. It is possible that when occurring in the presence of hypertension, repetitive sympathetic response to PLMS may have a blunted effect because the arterial system is primed to pressure variability. Furthermore, use of adrenergic blocking medication, common in the hypertensive population, may have mitigated responses to repetitive sympathetic surges at night. Our work suggests the need for further experimental research to clarify whether background differences in blood pressure level and medication use might modify responses to PLMS.
The strong association between PLMI and incident PAD suggests that PLMS may preferentially contribute to peripheral arteriopathy, which in turn may increase cardiovascular risk. In this analysis, PAD included arterial occlusion, rupture, or dissection and vascular surgery in any major artery. It is notable that persons with PLMS and RLS often complain of cold feet, a symptom attributed to increased vasoreactivity. 37 Additionally, peripheral vasoconstriction has been linked to PLMS in at least 1 small uncontrolled study. 38 Periodic limb movements could result in PAD through a mechanism of nocturnal hypertension. Repetitive elevations in blood pressure may directly damage endothelium or alter vasoreactivity through mechanical stress. Alternatively, PLMS and sympathetic hyperactivity may lead to a release of inflammatory mediators, stimulating both lipolysis and glycolysis and thus promoting endothelial damage and atherosclerosis. In fact, levels of lipoprotein-associated phospholipase A2, a marker for atherosclerosis, and C-reactive protein have recently been shown to be increased in the setting of PLMS. 39 It is worth noting that PLMAI was not associated with incident PAD, perhaps because of the low PAD event rate.
Although causality is difficult to discern from observational data, the evidence that PLMS preceded the development of cCVD or PAD is consistent with its causal role in vascular disease. Furthermore, the results suggest that PLMS may increase risk of cardiovascular and peripheral vascular disease through a mechanism other than daytime hypertension. Although our analyses utilized longitudinal data, it is possible that PLMS resulted from unrecognized cardiovascular disease or other unmeasured confounders. Whether PLMS directly increase vascular disease risk or are a marker of a generalized disorder of vasoreactivity requires further investigation.
This study has several strengths. Enrollment of these community-dwelling men was not determined on the basis of PLMS or cardiovascular disease risk, and for this reason, the findings can be generalized to elderly men. Incident cardiovascular disease was ascertained rigorously by a physical adjudicator unaware of the sleep study results. Finally, adjustment for multiple confounders, including major cardiovascular risk factors, was made. It is worth noting that the observed prevalence of PLMI Ͼ5 (70.9%) was significantly higher than previously reported. 2 This difference could have been secondary to the older age of the subject population in this cohort, but an overestimation of limb movements by piezoelectric sensors cannot be ruled out. Additionally, overscoring of PLMS cannot be ruled out because scoring allowed the inclusion of leg movements if, when occurring in a cluster, there were leg movements that occurred between respiratory events.
There are also limitations to consider in the interpretation of these findings. Although the associations of PLMI and PLMAI level and incident cCVD were statistically significant, there were other risk factors in the multivariate models with a larger effect size such as prevalent hypertension. The overall participation rate was quite high; however, because nonparticipants differed from participants in race, depression, and prevalent cardiovascular disease, it is plausible that the exclusion of these individuals may have influenced the results. The cohort consisted of men Ͼ65 years of age who were predominantly white, so the results cannot be generalized to women, younger persons, or nonwhites. Information on RLS symptoms was not available. Although PLMS occur in Ϸ80% of RLS sufferers, they occur in several other conditions and often in the elderly without RLS symptoms. 2,10 -13 Therefore, whether these findings can be extrapolated to RLS is unclear. A single measurement of PLMS at baseline does not account for night-to-night variability and changes in PLMS over time. Furthermore, the period of follow-up was modest, limiting the number of incident events and reducing precision in estimates, particularly CBD, CHD, and hypertension.
Conclusions
The findings of the present study provide evidence that PLMS frequency is associated with incident cardiovascular disease in community-dwelling elderly men. This observational study does not address causality. Future intervention studies are required to further address the potential role of PLMS treatment in the prevention of cCVD and to further understand the pathogenesis of vascular disease in individuals with PLMS.
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